摘要胰腺癌是转移倾向明显的高度恶性肿瘤，手术治疗有效但复发率高。通过新辅助治疗，部分患者可实现降期、增加切缘阴性率、降低淋巴结阳性率、减少血管侵犯等，但存在增加手术难度、延误手术时机、疗效评估指标不成熟等争议。具有高危因素的可切除胰腺癌患者可积极行新辅助治疗，交界可能切除的病例建议新辅助治疗，同时转化治疗可能改善晚期胰腺癌患者预后。晚期胰腺癌一线化疗方案FOLFIRINOX可用于新辅助治疗。

abstractsPancreatic adenocarcinoma is a malignant disease with considerable metastatic potential. While surgical resection can be potentially curative,tumor recurrence remains an important cause of treatment failure. Neoadjuvant chemotherapy can increase rate of resectability by decreasing tumor burden and decrease recurrence rate by clearing microscopic disease in lymph nodes and vessels. Currently,neoadjuvant therapy is recommended for patients with resectable who has signs of high risks or borderline resectable pancreatic adenocarcinoma. However,no consensus exists in current literature on the evaluation of treatment response or operative timing. FOLFIRINOX has recently emerged as an effective chemotherapy regimen in several large clinical trials.